Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test

Novo Nordisk (NYSE:NVO) aims to expand its Wegovy obesity drug market into the pediatric sector with the STEP Young trial. This study showed semaglutide, Wegovy's active ingredient, resulted in 40.4% of children no longer being classified as obese after 68 weeks, compared to none on placebo. The trial met its primary endpoint, demonstrating semaglutide's effectiveness in reducing body mass index.

However, lifestyle modifications like diet and exercise were also crucial. While GLP-1 weight-loss drugs are not approved for children under 12 in the U.S., a report from Pediatrics journal showed a massive increase in prescribing for children aged 8 to 11 with obesity and no diabetes. This suggests that expanding into this market could be a significant opportunity for Novo.

The timing is crucial as Novo aims to regain ground against Eli Lilly in the obesity market. Novo's CagriSema, another obesity drug candidate, failed to meet its primary endpoint in the REDEFINE 4 trial. Nevertheless, the STEP Young program allows Novo to expand semaglutide into a new age group, avoiding reliance on a new molecule.

However, there are risks, including regulatory approval, physician and parental acceptance, and reimbursement. While hedge funds are broadly interested in Novo, conviction is mixed, with some funds reducing their holdings. The STEP Young program could be a valuable extension of the Wegovy franchise, but the investment case hinges on whether clinical success translates into lasting commercial growth.